71.14 USD
-2.51 (-3.41%)
69.9 USD
-1.24 (-1.74%)
ChartMill assigns a Buy % Consensus number of 86% to TARS. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 88.63. This target is 24.58% above the current price.
- TARS was analyzed by 16 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about TARS.
- In the previous month the buy percentage consensus was at a similar level.
- TARS was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-09 | Barclays | Initiate | Overweight |
| 2025-11-20 | Mizuho | Initiate | Outperform |
| 2025-11-05 | Guggenheim | Maintains | Buy -> Buy |
| 2025-10-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-05 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-05-02 | Guggenheim | Maintains | Buy -> Buy |
| 2025-03-06 | Jefferies | Maintains | Buy -> Buy |
| 2025-02-26 | Guggenheim | Maintains | Buy -> Buy |
| 2025-02-26 | Barclays | Maintains | Overweight -> Overweight |
| 2025-02-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-24 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-02-10 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-01-27 | Barclays | Maintains | Overweight -> Overweight |
| 2025-01-22 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-11-15 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-11-14 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-08-09 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-05-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-05-10 | Barclays | Maintains | Overweight -> Overweight |
| 2024-05-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-03-06 | Jefferies | Maintains | Buy -> Buy |
| 2024-02-29 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-02-28 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-02-28 | Barclays | Maintains | Overweight -> Overweight |
| 2024-02-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-20 | Goldman Sachs | Initiate | Neutral |
| 2023-11-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-09-11 | Guggenheim | Maintains | Buy -> Buy |
| 2023-08-14 | Guggenheim | Reiterate | Buy -> Buy |
| 2023-08-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
TARSUS PHARMACEUTICALS INC / TARS FAQ
Can you provide the average price target for TARSUS PHARMACEUTICALS INC stock?
16 analysts have analysed TARS and the average price target is 88.63 USD. This implies a price increase of 24.58% is expected in the next year compared to the current price of 71.14.
Can you provide the consensus rating for TARSUS PHARMACEUTICALS INC stock?
The consensus rating for TARSUS PHARMACEUTICALS INC (TARS) is 86.25 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed TARSUS PHARMACEUTICALS INC (TARS)?
The number of analysts covering TARSUS PHARMACEUTICALS INC (TARS) is 16.